Vitamin C

• Preventing and treating scurvy and correcting vitamin C deficiency (definitive)
• Supporting collagen synthesis, wound healing, and connective tissue
• Improving absorption of non-heme (plant-source) iron when taken with the meal
• Modestly shortening common-cold duration with regular daily intake
• Reducing cold incidence specifically in people under extreme physical stress (endurance athletes, soldiers in subarctic conditions)
• General antioxidant and daily nutritional insurance where dietary intake is low

Vitamin C (ascorbic acid) is a water-soluble essential vitamin uniquely required by humans, other primates, guinea pigs, fruit bats, and certain fish, most other species synthesize ascorbate endogenously from glucose. The loss of L-gulonolactone oxidase (the final enzyme in ascorbate biosynthesis) in primate evolution made dietary vitamin C essential, with scurvy as the dramatic deficiency syndrome that historically affected sailors, soldiers, and others lacking fresh produce. The molecular function of ascorbate centers on its role as a one- and two-electron donor, it readily gives up electrons to oxidized molecules, regenerating their reduced forms. This electron-donor capacity enables ascorbate to function as cofactor for at least fifteen mammalian enzymes (including several iron-dependent and copper-dependent enzymes), as a general intracellular and extracellular antioxidant, and as a regenerator of other antioxidants (notably vitamin E in cell membranes). The most clinically important enzymatic cofactor roles span collagen synthesis (proline and lysine hydroxylases require ascorbate), carnitine biosynthesis (two ascorbate-dependent hydroxylases convert lysine to carnitine for fatty acid mitochondrial transport), norepinephrine biosynthesis (dopamine beta-hydroxylase converts dopamine to norepinephrine), peptide hormone amidation (oxytocin, vasopressin, cholecystokinin require ascorbate-dependent amidation for activation), and HIF (hypoxia-inducible factor) regulation through prolyl hydroxylases. The collagen synthesis role explains the connective tissue manifestations of scurvy, defective collagen produces vascular fragility, bleeding gums, impaired wound healing, and the classical "corkscrew hair" appearance. The norepinephrine biosynthesis role explains the cognitive and mood manifestations of severe deficiency. The antioxidant function spans every tissue but is particularly important in tissues with elevated oxidative stress, neutrophils (which accumulate ascorbate to substantial concentrations during phagocytosis), adrenal cortex (highest ascorbate concentration of any tissue), brain, ocular lens, and lung. The therapeutic dose-response curve is unusually complex: plasma ascorbate plateaus around 200-250mcmol/L at oral intakes above ~400mg/day due to renal clearance saturation, but IV administration can produce pharmacological plasma levels (>1mmol/L) that activate prooxidant chemistry (Fenton reaction with iron, hydrogen peroxide generation), the basis of the high-dose IV ascorbate cancer adjunct evidence base. Vitamin C's pharmacology spans these distinct regimes (deficiency prevention at single-digit mg; physiological supplementation at 100-1000mg; pharmacological IV at 25-100g) with different evidence bases and clinical implications at each level.

Routine vitamin C supplementation should account for the unusual pharmacology: plasma ascorbate saturates around 200-250 mcmol/L at oral intakes above ~400mg/day, with renal clearance increasing sharply above this threshold. This means doubling oral dose from 1g to 2g produces minimal additional plasma elevation, substantial portions are excreted unchanged. The RDA of 90mg/day men, 75mg/day women (with additional 35mg for smokers) is readily achieved through dietary citrus, peppers, broccoli, and other vitamin C-rich foods. Modest supplementation (100-500mg/day) provides antioxidant buffer without exceeding the absorption plateau. Higher chronic doses (1-3g/day) are used in some functional medicine protocols but provide diminishing returns and increase risk of GI upset, kidney stones in susceptible users, and (at extreme doses) interference with various lab tests. Divided dosing (250mg 3-4 times daily) modestly improves cumulative absorption versus single large doses. Take with or without food; absorption is acceptable either way. The pharmacological IV high-dose regime is fundamentally different, IV administration bypasses the renal clearance saturation and produces plasma concentrations >1 mmol/L that activate prooxidant chemistry. Cancer integrative protocols use 25-100g per infusion, 2-3 times weekly; clinical specialty research has explored higher doses still. G6PD deficiency screening before high-dose IV use is reasonable (theoretical hemolysis concern though clinical relevance debated). The Upper Limit (2000mg/day adults) reflects GI tolerance and oxalate kidney stone risk rather than systemic toxicity; many users tolerate higher chronic doses without issues.

RDA adult men

90mg/day

RDA adult women

75mg/day

Smokers (additional)

+35mg/day

Pregnancy / lactation

85-120mg/day

Plasma saturation

~200-250 mcmol/L at >400mg/day oral

Standard supplementation

100-500mg/day

Higher functional medicine doses

1-3g/day in divided doses

Upper Limit (UL)

2000mg/day

• Ascorbic Acid (Standard)

  Rating: gold

  The standard pharmaceutical form. White crystalline powder, water-soluble, mildly acidic (citric-acid level acidity). Used in essentially all vitamin C clinical trials and in pharmaceutical preparations. Cheap, effective, well-evidenced. The mildly acidic profile can cause GI upset at high doses; buffered forms address this.

• Sodium Ascorbate (Buffered)

  Rating: good

  Sodium salt of ascorbic acid, neutral pH, no GI acidity concerns. Sodium content modest at typical doses but worth considering in salt-restricted users (1g sodium ascorbate delivers ~110mg sodium). Common pharmaceutical IV form (Cenovis IV) at high doses.

• Calcium Ascorbate (Ester-C)

  Rating: good

  Calcium salt of ascorbic acid plus dehydroascorbate metabolites, marketed as Ester-C with claims of better absorption and 24-hour activity. Some absorption advantage but clinical superiority over standard ascorbic acid not definitively established. Buffered form with neutral pH. Calcium content modest.

• Liposomal Vitamin C

  Rating: good

  Vitamin C encapsulated in phospholipid liposomes for enhanced cellular uptake. Comparative absorption studies suggest modest pharmacokinetic advantage at high oral doses (>2g) where standard ascorbic acid faces absorption saturation. Premium pricing; clinical superiority is suggestive rather than definitive.

• IV Vitamin C (Pharmaceutical High-Dose)

  Rating: gold

  Intravenous administration produces plasma concentrations 25-70x higher than achievable orally, pharmacological levels (>1 mmol/L) that activate prooxidant chemistry. Used in integrative cancer care (typically 25-100g per infusion, 2-3 times weekly), sepsis trials (1.5-6g/day in clinical studies), and severe burn protocols. Specialist administration; G6PD deficiency screening recommended before high-dose use.

• Whole Food Vitamin C (Amla, Acerola, Camu Camu)

  Rating: good

  Vitamin C from whole-food sources including amla (Indian gooseberry), acerola cherry, camu camu, and rose hips. Often marketed for "natural" sourcing and bioflavonoid content. Bioavailability comparable to synthetic ascorbic acid; bioflavonoids may provide modest additional antioxidant content. Premium pricing.

• Vitamin C + Bioflavonoids

  Rating: good

  Combination with citrus bioflavonoids, rutin, hesperidin, quercetin. Mechanistically reasonable, bioflavonoids provide additional antioxidant and vascular support; some evidence for synergistic action with vitamin C in capillary function. Reasonable formulation; not essential for general vitamin C supplementation.

• Vitamin C Effervescent (Emergen-C, Airborne)

  Rating: caution

  Consumer mass-market effervescent vitamin C products. Often combined with B vitamins, electrolytes, and herbal blends. Sugar content can be substantial in some products. The 1000mg vitamin C per serving exceeds typical supplementation needs; the "cold prevention" marketing exceeds the underlying evidence base.

• Scurvy prevention and treatment

  Strength of evidence for this group: strong

  The classical use case, supplementation at modest doses (50-200mg/day) prevents and reverses scurvy. Rare in developed populations but persists in specific risk groups (elderly with limited diets, severe alcohol use disorder, restrictive eating, institutional settings, parenteral nutrition). Specialist coordination for clinical scurvy.

• Daily general supplementation (healthy adults)

  Strength of evidence for this group: modest

  Most adults can readily achieve adequate vitamin C intake through diet (citrus fruits, peppers, broccoli, kiwi, strawberries provide substantial amounts). Routine supplementation at modest doses (100-500mg/day) provides antioxidant buffer above RDA without exceeding the saturation plateau. Higher chronic doses produce diminishing returns due to renal clearance saturation.

• Common cold (regular supplementation)

  Strength of evidence for this group: modest

  Hemilä Cochrane review: regular vitamin C does not prevent cold incidence in general population. Modest reduction in cold duration (8% adults, 14% children) with regular use. Specific protective benefit in cohorts with extreme physical stress. Reasonable in athletes with heavy training, military, and other high-stress contexts.

• Common cold (therapeutic at symptom onset)

  Strength of evidence for this group: cautious

  High-dose vitamin C started at symptom onset (1-2g/day) produces limited evidence for symptom duration reduction in general population, substantially weaker than chronic supplementation evidence. Often combined with zinc lozenges for which there is better evidence.

• Iron absorption support (non-heme iron)

  Strength of evidence for this group: strong

  Vitamin C substantially enhances non-heme iron absorption (vegetable/supplement iron). 250mg ascorbic acid with iron supplements or iron-containing meals can double absorption. Particularly relevant for vegetarian/vegan iron strategies and iron deficiency anemia treatment.

• Wound healing (deficient or compromised)

  Strength of evidence for this group: modest

  Vitamin C is required for collagen synthesis; deficiency impairs wound healing. Supplementation in deficient cohorts (severe burns, surgical wounds, pressure ulcers) supports healing. Routine supplementation in non-deficient users does not accelerate wound healing.

• Smokers

  Strength of evidence for this group: modest

  Smokers have lower vitamin C status due to increased oxidative stress and direct cigarette smoke damage to vitamin C. RDA is increased by 35mg/day for smokers. Modestly higher supplementation reasonable; smoking cessation remains the more impactful intervention.

• IV high-dose cancer adjunct

  Strength of evidence for this group: cautious

  Integrative oncology use case based on Padayatty 2004 pharmacokinetic work and subsequent clinical research. Hoffer 2008 and other Phase I/II trials establish safety profile. Clinical efficacy for hard endpoints (survival) remains preliminary; integrative use as adjunct to standard cancer care under specialist coordination.

• Sepsis (high-dose IV)

  Strength of evidence for this group: cautious

  Marik 2017 generated enormous interest; subsequent rigorous RCTs (VITAMINS, VICTAS, ATESS) failed to replicate the initial dramatic effects. The Marik protocol is no longer recommended in mainstream sepsis guidelines. Textbook M-08 Replication-Discordance case.

• COVID-19 outpatient

  Strength of evidence for this group: cautious

  Thomas 2021 outpatient trial: 8000mg vitamin C + 50mg zinc did not reduce symptom duration versus placebo. Not supported as standard outpatient COVID intervention. Severe disease and hospital protocols may have different considerations.

• Iron (Non-Heme)

  Interaction: synergy

  The most clinically important vitamin C pairing. 250mg vitamin C with iron supplement or iron-containing meal substantially enhances non-heme iron absorption. Particularly relevant for iron deficiency anemia treatment and vegetarian iron strategies.

• Vitamin E

  Interaction: synergy

  Vitamin C regenerates oxidized vitamin E (alpha-tocopheroxyl radical) back to active form. Mechanistically complementary antioxidant pairing in cell membranes. Common in comprehensive antioxidant supplementation.

• Glutathione / N-Acetylcysteine

  Interaction: synergy

  Vitamin C and glutathione are interconnected antioxidant systems, each regenerates the other. NAC provides cysteine for glutathione synthesis. Common in comprehensive antioxidant and detoxification protocols.

• Zinc

  Interaction: synergy

  Both support immune function through complementary mechanisms. Common combination in cold and respiratory infection contexts (though Thomas 2021 showed negative results for high-dose combination in outpatient COVID-19).

• Quercetin and Bioflavonoids

  Interaction: synergy

  Mechanistically complementary antioxidants. Quercetin specifically may enhance some vitamin C effects on capillary function and inflammation. Common in comprehensive cardiovascular and immune protocols.

• Iron (Hemochromatosis Users)

  Interaction: avoid

  Vitamin C enhances iron absorption, substantial concern for users with hereditary hemochromatosis or other iron overload conditions. High-dose vitamin C may accelerate iron accumulation in these users. Specialist coordination essential.

• Aluminum-Containing Antacids

  Interaction: caution

  Vitamin C may enhance aluminum absorption from antacids. Relevant for users with kidney disease where aluminum accumulation is concerning.

• Warfarin

  Interaction: caution

  Very high-dose vitamin C (>10g/day) has been reported to reduce warfarin effect in case reports. Clinical significance modest at typical supplementation doses; coordinate with prescribing physician at very high doses.

• Statins

  Interaction: neutral

  Some studies suggest vitamin C may modestly reduce statin LDL-lowering effect; clinical relevance is small at typical doses. Generally compatible combination.

Look for: explicit ascorbic acid (or specified salt form) content disclosed clearly; USP or NSF third-party verification; reasonable price per gram (vitamin C is genuinely inexpensive at commodity pricing); buffered form if GI-sensitive (sodium ascorbate, calcium ascorbate); divided-dose products for higher chronic intake (250-500mg per serving rather than 2000mg single doses); no excessive sugar content in effervescent products. Avoid: proprietary "immune blends" obscuring vitamin C dose; products marketed with cold prevention claims that exceed evidence base; very high single-dose products (>1g per serving) producing GI distress; whole-food vitamin C products at premium pricing without specific quality differentiation; effervescent products with substantial added sugar; products from manufacturers without third-party testing disclosure.

Vitamin C's history is among the most consequential in nutritional science. Scurvy was the dominant occupational disease of long-distance seafaring from the 15th-19th centuries, historical estimates suggest scurvy killed more sailors than naval combat, storms, and shipwrecks combined. The Portuguese, Dutch, and British East India Companies had substantial commercial interest in scurvy prevention; various dietary interventions were tried with mixed results. James Lind's 1747 trial aboard HMS Salisbury is considered the first controlled clinical trial in medical history, comparing six interventions in twelve scorbutic sailors. The dramatic recovery in the citrus group (oranges and lemons) versus other interventions provided foundational evidence, though the mechanism (vitamin C) remained unknown for nearly two centuries. The biochemical era began with Casimir Funk's "vitamin" concept (1912), the proposal that specific dietary factors prevented diseases like scurvy, beriberi, and pellagra. Vitamin C's isolation came through Albert Szent-Györgyi's work on adrenal cortex extracts and paprika in the late 1920s. Szent-Györgyi initially named the substance "hexuronic acid" before connecting it to scurvy prevention; subsequent collaboration with Charles Glen King at the University of Pittsburgh established the vitamin C identity. The 1937 Nobel Prize in Physiology or Medicine recognized Szent-Györgyi's vitamin C work alongside other contributions; Walter Norman Haworth received the Chemistry Nobel the same year for ascorbic acid structural characterization. The controversy era began with Linus Pauling's 1970 book "Vitamin C and the Common Cold", proposing megadose vitamin C (1-2g/day) for cold prevention. Pauling's scientific reputation (Nobel Prizes in Chemistry 1954 and Peace 1962) gave substantial weight to claims that subsequent evidence did not fully support. The 1976 Pauling-Cameron cancer trial extended the megadose hypothesis to terminal cancer, generating decades of subsequent controversy. The Mayo Clinic trials (Moertel 1979, 1985) provided rigorous negative evidence for oral high-dose vitamin C in cancer, but Pauling's response (that Mayo had used previously-treated patients while his trial used chemotherapy-naive patients) kept the controversy alive. The pharmacokinetic resolution came through Mark Levine's NIH group in the 2000s. Padayatty 2004 demonstrated that IV administration produces plasma concentrations 25-70x higher than oral administration, establishing that the Mayo oral trials and the high-dose IV cancer hypothesis were fundamentally different pharmacological regimes. This revived serious clinical research on high-dose IV vitamin C as cancer adjunct. Hoffer 2008 and subsequent trials established Phase I/II safety; the integrative oncology IV vitamin C category emerged as established specialty practice. The Marik sepsis saga (2017-2021) became a textbook M-08 Replication-Discordance case in critical care. Paul Marik's 2017 before-after study at Eastern Virginia Medical School reported dramatic mortality reduction with vitamin C + thiamine + hydrocortisone "metabolic resuscitation" for sepsis. The initial finding catalyzed enormous interest and rapid clinical adoption. Subsequent rigorous RCTs (VITAMINS, VICTAS, ATESS) uniformly failed to replicate the dramatic before-after effects. The Marik protocol is no longer recommended in mainstream sepsis guidelines. Marik himself subsequently became controversial for COVID-19 advocacy positions outside the vitamin C context. The story illustrates the M-08 pattern dramatically, pivotal positive evidence, enthusiastic clinical adoption, subsequent failed replication, and partial commercial/clinical adjustment. The COVID-19 era brought enormous attention to vitamin C supplementation. Early functional medicine guidance heavily emphasized vitamin C; observational studies suggested correlation between vitamin C status and COVID outcomes; some inpatient IV vitamin C protocols emerged. The Thomas 2021 outpatient trial showed no symptom duration benefit for outpatient mild COVID at 8000mg vitamin C + 50mg zinc. Inpatient and severe disease contexts may differ but outpatient supplementation is not supported.

1. 1747Lind scurvy trial, first controlled clinical trial in medicine
2. 1912Funk introduces "vitamin" concept
3. 1928-1933Szent-Györgyi isolates ascorbic acid; Haworth characterizes structure
4. 1937Nobel Prize for vitamin C discovery (Szent-Györgyi, Haworth)
5. 1970Pauling publishes "Vitamin C and the Common Cold"
6. 1976Pauling-Cameron terminal cancer trial
7. 1979, 1985Mayo Clinic Moertel trials (negative for oral high-dose in cancer)
8. 2004Padayatty IV pharmacokinetics revives high-dose hypothesis
9. 2008Hoffer Phase I IV cancer trial
10. 2013Hemilä Cochrane cold review consolidates evidence
11. 2017Marik sepsis "metabolic resuscitation" hypothesis
12. 2020-2021VITAMINS, VICTAS, ATESS RCTs fail to replicate Marik
13. 2021Thomas outpatient COVID-19 trial (negative)

• Whether high-dose IV vitamin C will produce hard endpoint cancer outcomes (survival, time to progression) in larger Phase III trials, current evidence is largely Phase I/II safety and feasibility.
• Whether the Marik sepsis story will produce any retained therapeutic role, current mainstream guidelines do not include the Marik protocol but ongoing research in specific sepsis subtypes continues.
• Whether liposomal vitamin C provides clinically meaningful advantages over standard ascorbic acid at typical supplementation doses, most evidence suggests modest pharmacokinetic advantage with limited clinical significance.
• Whether the iron absorption enhancement is clinically beneficial in iron-replete users, most evidence focuses on iron-deficient cohorts where benefit is substantial.
• Whether routine high-dose vitamin C supplementation produces meaningful oxidative stress reduction at the tissue level or whether antioxidant defenses operate independently of supplementation status in well-nourished individuals.
• Whether vitamin C has applications in cardiovascular prevention beyond the established iron absorption and antioxidant mechanisms, preliminary evidence in endothelial function is limited.
• Whether the oxalate kidney stone concern is meaningfully elevated by typical supplementation doses (1-3g) or only by extreme doses (>5g chronic).
• How best to integrate vitamin C with chemotherapy, interactions with specific chemotherapy agents remain incompletely characterized; integrative oncology guidance varies.

Universally available globally as dietary supplement, food fortification, pharmaceutical product, and food enhancement. Legal under DSHEA in the United States and equivalent regulations globally. Not on WADA prohibited list. Pharmaceutical vitamin C is widely available; high-dose IV preparations (Cenovis, Mylan) are pharmaceutical products requiring specialist administration. Major retail brands include Nature's Bounty, NOW Foods, Thorne, Pure Encapsulations, Solgar, Designs for Health, and most multivitamin manufacturers. Effervescent consumer products (Emergen-C by Pfizer, Airborne) dominate the cold/immune mass market with substantial commercial scale despite marketing claims that exceed the underlying evidence base. Production of synthetic ascorbic acid (Reichstein process) is well-established at commodity pricing; most global production is in China. Whole-food vitamin C from amla, acerola, camu camu commands premium pricing but represents a small market share. Integrative oncology IV high-dose protocols are increasingly available in specialty practice though not covered by most insurance.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Status

Water-soluble essential vitamin

Endogenous synthesis (humans)

None (loss of L-gulonolactone oxidase in primate evolution)

RDA adult men

90mg/day

RDA adult women

75mg/day

Smokers (additional)

+35mg/day

Upper Limit

2000mg/day

What follows is unfinished work on our side, not a finding about Vitamin C. A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.